Relevant Research in Support of Vivix^®

The Rejuvetrol™ Patent Pending Blend in VIVIX is based on the latest scientific studies and emerging research as follows:

• Scientists around the world have been investigating polyphenolic compounds such as resveratroland have shown in laboratory studies that these compounds can potentially improve health and well-being.*1
• Public health agencies such as the National Institutes of Health (NIH), the National Cancer Institute (NCI), the National Institute on Aging(NIA) as well as the United States Department of Agriculture (USDA) have reviewed and studied the potential lifestyle benefits of phenolic compounds.2
• The National Institutes of Health (NIH) spent over $2.4 billion in 2007 alone to further the scientific understanding of the processes of aging. Towards this end, the National Institute on Aging (NIA) has taken the lead to further the understanding of aging and supports some of the laboratory research on resveratrol and improved health.*3,2
• A landmark laboratory study from Harvard Medical School and published in Nature in 2006 suggests that resveratrol improves energy balance and may protect against cellular aging processes in mice.*4
• Later this study data was converted into a human dose equivalent and published by a research team in a 2007 online and 2008 print journal issue of the Federation of American Societies for Experimental Biology (FASEB). 5,6
• More recent studies published this year in PLoS ONE, June 2008 and Cell Metabolism, August 2008 indirectly confirm the potential positive effects and intake levels as well.7,8
• Specifically, researchers from the National Institute on Aging and other institutions published in the 2008 issue of Cell Metabolism data confirming that resveratrol may mimic, in laboratory studies, almost all of the effects of dietary or calorie restriction.  This process may activate genetic regulators of cellular longevity pathways, which may have positive effects on cellular health and metabolism.*8
• Most importantly, the Linus Pauling Institute at Oregon State University and other organizations explain that ‘resveratrol is not known to be toxic or cause adverse effects in humans.  Most prominently, safety data from animal studies were published in Toxicoll Sciences in 2004 and in the Journal of Nutrition in 2002. Furthermore, a recent trial that evaluated the safety of oral resveratrol in ten subjects found a single dose from 0.5 to 5 grams resulted in no serious adverse effects.  The study was published in 2007 in Cancer Epidemiol Biomarkers Prev.9.10,11,12

References:

1. PubMed, a service of the National Library of Medicine, located at the National Institutes of Health, visit at http://www.ncbi.nlm.nih.gov/pubmed/.


2. National Institutes of Health at http://health.nih.gov/, National Cancer Institute at http://www.cancer.gov/, National Institute on Aging at http://www.nia.nih.gov/. Department of Agriculture at http://www.ars.usda.gov/main/main.htm.


3. U.S. Department of Health and Human Services, National Institutes of Health:  Estimates of funding for various diseases, conditions, research areas. Table Updated February 2008.


4. Baur JA, Pearson KJ, Price NL, and Jamieson HA, Sinclair DA et al: Resveratrol improves health and survival of mice on a high-calorie diet.  Nature 2006 Nov 16; 444(7117):337-42.


5. Reagan-Shaw S et al:  Dose Translation from animal to human studies revisited. The FASEB Journal published online before print as doi: 10.1096/fj.07-9574LSF, October 17, 2007.


6. Reagan-Shaw S et al:  Dose translation from animal to human studies revisited. The FASEB Journal 2008; 22:659-661.


7. Barger JL et al: A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE, June 2008; 3, 6, 1-10.


8. Pearson K et al:  Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.  Cell Metabolism, August 2008; 8, 1-12.


9. Linus Pauling Institute at Oregon State University, Micronutrient Information Center, Resveratrol, at http://lpi.oregonstate.edu/infocenter/phytochemicals/resveratrol/, updated version June 2008.


10. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS: Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82(2):614-619.


11. Juan ME, Vinardell MP, and Planas JM:  The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr. 2002;132(2):257-260.


12. Boocock DJ, Faust GE, Patel KR, et al:  Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246-1252.